CN-122011163-A - Shark-derived nanobody targeting FPV-VP2 protein and application thereof

Abstract

The invention discloses a shark source nano-antibody targeting FPV-VP2 protein and application thereof. The amino acid sequence of the shark source nano antibody is shown as SEQ ID NO. 1. The shark source VNAR nano antibody has the advantages of small molecular weight, high affinity, high stability, easy genetic engineering improvement, low production cost and the like.

Inventors

• ZHANG RONGQING
• GU WENXUE
• WANG HAO
• Jin Siyin
• YAO LIPING

Assignees

• 浙江清华长三角研究院

Dates

Publication Date

20260512

Application Date

20250828

Claims (8)

1. 1. A shark source nano-antibody targeting FPV-VP2 protein is characterized in that the amino acid sequence of the shark source nano-antibody is shown as SEQ ID NO. 1.
2. 2. A biomaterial comprising at least one of the following: a) A nucleotide for encoding the shark source nanobody of claim 1; b) An expression vector comprising the nucleotide; c) A recombinant prokaryotic host comprising said nucleotide or said expression vector.
3. 3. Use of a shark source nanobody according to any one of claims 1 or a biomaterial according to claim 2 for the preparation of a detection reagent for feline panleukopenia virus.
4. 4. The method of claim 3, wherein the assay comprises an ELISA, a chemiluminescent immunoassay, a rapid diagnostic test strip, a fluorescent immunoassay, or an immunosensor assay.
5. 5. The method of claim 3, wherein the VP2 capsid protein of the feline panleukopenia virus is the target of detection.
6. 6. Use of a shark source nanobody according to claim 1 or a biomaterial according to claim 2 for the preparation of a medicament for the prophylaxis and/or treatment of a disease caused by or associated with feline panleukopenia virus infection in an animal.
7. 7. The method of claim 6, wherein the animal is a cat or other host animal that is naturally challenged with a feline leukopenia virus.
8. 8. The method according to claim 6, wherein the therapeutic target is VP2 capsid protein of feline panleukopenia virus.

Description

Shark-derived nanobody targeting FPV-VP2 protein and application thereof The application relates to a shark source nano antibody targeting FPV-VP2 protein and application thereof, which are divisional applications of application number '2025112150192', application date '2025-08-28' and the application name 'the shark source nano antibody targeting FPV-VP2 protein'. Technical Field The invention belongs to the technical field of biology, and relates to a shark source nano-antibody of Feline Panleukopenia Virus (FPV) VP2 capsid protein and application thereof. Background The VNAR nano antibody of the new antigen receptor immunoglobulin variable region in the shark animal body can naturally recognize antigen molecules, and has the characteristics of small volume, stable property, capability of recognizing antigen hidden sites, easy transformation and the like. Compared with camel VHH nanobody, shark-source VNAR antibody has smaller molecular weight and higher stability, but has insufficient application and development in the fields of therapeutic drugs and diagnostic reagents due to factors such as long animal immune cycle and difficult preparation. Feline panleukopenia virus (also known as feline parvovirus, feline pestivirus, FPV) infection is a serious infectious disease occurring in cats and is often fatal to immunocompromised or unvaccinated animals such as kittens. Currently, conventional treatment regimens for feline panleukopenia virus infection are generally limited to supportive care, including body fluid supplementation, antibiotics, antiemetics, and anti-inflammatory agents, among others. Neutralizing antibodies are effective means of treating viral infections, and neutralizing antibodies are typically produced after acute infection, which can reduce the infectious capacity of the virus. Studies show that the treatment of the parvovirus neutralizing antibody can greatly improve the survival rate and recovery rate of animals infected by parvovirus. In 2023, month 5, the U.S. department of agriculture provided conditional access to the first canine parvovirus monoclonal antibody of ceruloplasmic reticulum, but no effective monoclonal antibody has yet been marketed by feline panleukopenia virus. The FPV-VP2 protein is 90% of the viral capsid protein and is capable of self-assembly to form virus-like particles, playing an important role in viral transmission and infection. VP2 is also the major antigen protein, and the N domain and the loop domain of VP2 contain several important B-cell epitopes, so that effective neutralizing antibodies can be induced in the virus infection process. Currently, there is no shark-derived nanobody targeting FPV-related proteins. Disclosure of Invention In order to solve the problems in the background technology, the invention provides a shark source nano-antibody targeting FPV-VP2 protein and application thereof. The variable region sequence (VNAR) of the shark source heavy chain antibody capable of combining with the FPV-VP2 capsid protein with high affinity, which is also called nano antibody or single domain antibody, can be used for preparing FPV therapeutic neutralizing antibody and also can be used for preparing FPV infection diagnostic reagent. The technical scheme adopted by the invention is as follows: 1. shark-derived nanobody targeting FPV-VP2 protein The amino acid sequence of the shark source nano antibody is a sequence shown as SEQ ID NO. 1. 2. Biological material The biological material comprises at least one of the following biological materials: a) Nucleotides for encoding shark source nanobodies as described above; b) An expression vector comprising the nucleotide; c) A recombinant prokaryotic host comprising said nucleotide or said expression vector. 3. Application of shark source nano antibody in biological material The shark source nano-antibody and the biological material can be used for preparing a detection reagent for feline panleukopenia virus. Further, the assays include, but are not limited to, enzyme-linked immunoassays, chemiluminescent immunoassays, rapid diagnostic test strips, fluorescent immunoassays, and immunosensor assays. Specifically, the detection target is VP2 capsid protein of feline panleukopenia virus. 4. Application of shark-derived nanobody or biological material The shark source nanobody and the biological material can be used for preparing a medicament capable of preventing and/or treating diseases caused by or related to feline panleukopenia virus infection in animals. In particular, the animal is a feline or other host animal that naturally states feline panleukopenia virus. Specifically, the therapeutic target is VP2 capsid protein of feline panleukopenia virus. The beneficial effects of the invention are as follows: 1. The antibody of the invention is a shark source VNAR nano antibody targeting the cat leukopenia virus for the first time, and compared with the traditional monoclonal antibody, the shark source VNAR nano